Quince Therapeutics Phase 3 NEAT trial misses primary endpoint; eDSP development halted

Quince Therapeutics, Inc.

Primary endpoint RmICARS p=0.0851; mean change from baseline -1.30 vs placebo.
Key secondary endpoint CGI-S also missed (p=0.522).
eDSP well tolerated; most common adverse events pruritis and pyrexia.
Company to cease clinical development of eDSP and explore available options.
Phase 3 NEAT trial enrolled 105 patients with Ataxia-Telangiectasia.

item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.